Medicine
Orkambi 125 mg/200 mg tablet
Orkambi 125 mg/200 mg tablet is a prescription medicine containing Ivacaftor and Lumacaftor for oral use, marketed by Vertex Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C - 25°C (68°F - 77°F), excursions permitted to 15°C - 30°C (59°F…
Key facts
- Active ingredient (INN)
- Ivacaftor and Lumacaftor
- Brand
- Orkambi
- Strength
- 125 mg/200 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 4 cartons
- Marketing authorisation holder
- Vertex Pharmaceuticals
- Manufacturer
- Vertex Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C - 25°C (68°F - 77°F), excursions permitted to 15°C - 30°C (59°F - 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- R07AX30 Ivacaftor and Lumacaftor
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 2 July 2015
- Identifiers
- RxCUI 1655928, 1655934, 1812468 +7DailyMed set ID 3fc1c40e-cfac-47a1-9e1a-61ead3570600NDC 51167-809Application NDA206038
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 carton in 1 box / 7 blister pack in 1 carton / 4 tablet, film coated in 1 blister pack | 51167-809-01 | Vertex Pharmaceuticals | 2 July 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ivacaftor and Lumacaftor
Clinical summary
Ivacaftor and Lumacaftor is a fixed-dose combination medicine indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. MedsAcross supplies Ivacaftor and Lumacaftor for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Ivacaftor and LumacaftorFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ORKAMBI prescribing information (Vertex Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Orkambi: European public assessment report (EPAR) · European Medicines Agency
Need Orkambi 125 mg/200 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.